ObsEva

ObsEva SA, a biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for women suffering from reproductive health and pregnancy. It is developing Linzagolix, an oral gonadotropin releasing hormone receptor antagonist that is in Phase III clinical trial for the treatment of pain associated with endometriosis and heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women. The company is also involved in developing Ebopiprant, an oral and selective prostaglandin F2a, or PGF2a receptor antagonist, which is in Phase II clinical trial as a once daily treatment for preterm labor in weeks 24 to 34 of gestational age; and Nolasiban, an oral oxytocin receptor antagonist that is in Phase I clinical trial to enhance clinical pregnancy and live birth rates in women undergoing in vitro fertilization. ObsEva SA was founded in 2012 and is headquartered in Geneva, Switzerland.

ObsEva's mission is to make a difference to the lives of women and their families worldwide by developing and supplying innovative reproductive healthcare solutions.

ObsEva’s vision is to become the leading provider of reproductive healthcare solutions for women and their families worldwide.

ObsEva has earned multiple awards for its role in developing a novel therapy for women’s reproductive health including the Frost & Sullivan Global Award for Best Research Based Pharmaceutical Company 2019, and the Red Herring Top 100 Europe award 2019.